UNIPHARMA INSIGHTS
Search insights
Signal flow
CDC has told TB programs to diversify suppliers, use inter-program loans, and consider stockpile access as rifampin shortages and local supply gaps persist.
FDA can ease some shortage pressures through expedited reviews, foreign sourcing and expiry extensions, but it cannot run the market or compel supply.
A UK Tier 3 shortage alert for cisplatin and carboplatin is pushing trusts to source unlicensed imports and tighten aseptic and QA controls.
FDA’s latest shortage guidance sharpens expectations on reporting, risk plans, and expedited reviews, with direct consequences for suppliers, buyers, and U.S. market access.
FDASIA reshaped how the FDA manages drug shortages, with earlier manufacturer reporting, public non-compliance letters, and faster mitigation routes during supply disruption.
The UK has brought forward its MHRA-NICE aligned pathway, tightening the link between licensing and HTA and changing launch planning for pharma companies.
Reference pages
8 pages visible
Aspirin is tracked by UniPharma because changes in supply, manufacturing, regulation, or demand can affect sourcing and market decisions for pharma teams operating across Europe and the UK.
Open pageChlorphenamine is tracked by UniPharma because changes in supply, manufacturing, regulation, or demand can affect sourcing and market decisions for pharma teams operating across Europe and the UK.
Open pageMexiletine is tracked by UniPharma because changes in supply, manufacturing, regulation, or demand can affect sourcing and market decisions for pharma teams operating across Europe and the UK.
Open pageDrug shortage supplier is tracked by UniPharma when it has a clear effect on sourcing, regulation, access, or commercial execution for pharma teams.
Open pageEarly Access Medicine is tracked by UniPharma when it has a clear effect on sourcing, regulation, access, or commercial execution for pharma teams.
Open pageUnlicensed Medicine Supply is tracked by UniPharma when it has a clear effect on sourcing, regulation, access, or commercial execution for pharma teams.
Open pageUnlicensed Medicines is tracked by UniPharma when it has a clear effect on sourcing, regulation, access, or commercial execution for pharma teams.
Open pageOncology is monitored by UniPharma because shifts in demand, reimbursement, regulation, competition, or supply priorities can reshape procurement and launch planning.
Open pageContact us
Bring us the access challenge, the shortage pressure or the regulated logistics brief. We will turn it into a clean operating plan.
